Therapeutic Area
Oncology CDMOs
Compare CDMOs with oncology manufacturing experience for cytotoxic compounds, antibody-drug conjugates (ADCs), and targeted therapies. Filter by containment level, modality, and scale.
386 companies listed
About Oncology Drug Manufacturing
Oncology is the largest therapeutic area by R&D spend, with over 2,000 drugs in clinical development globally. Manufacturing oncology products demands specialized capabilities: cytotoxic handling for traditional chemotherapy agents, high-potency containment for targeted small molecules, and bioconjugation expertise for the growing ADC (antibody-drug conjugate) pipeline.
Containment is non-negotiable. Most oncology APIs have occupational exposure limits (OELs) below 10 micrograms per cubic meter, requiring OEB4 or OEB5 engineering controls. This means dedicated facilities with isolators, continuous liner systems, split-butterfly valves, and validated cleaning procedures to prevent cross-contamination. Not every CDMO claiming "potent compound handling" can actually operate at OEB5 levels.
ADCs represent a unique manufacturing challenge. They combine biologics (monoclonal antibody production), small molecule chemistry (cytotoxic payload synthesis and linker chemistry), and bioconjugation (attaching payload to antibody). Few CDMOs can handle all three steps in-house. Most ADC sponsors work with 2-3 specialized CDMOs and manage the tech transfer between them.
Companies (386)
NorthStar Medical Radioisotopes, LLC
United States
NorthStar Medical Radioisotopes is a US-based commercial-stage company focused on the development, production, and commercialization of radiopharmaceuticals. Operating a dedicated Radiopharmaceutical CDMO/CMO on its 55-acre Beloit, Wisconsin campus, NorthStar develops novel non-reactor-based production processes for therapeutic and diagnostic radioisotopes including Molybdenum-99, Copper-67, and Actinium-225. The company has 14 FDA-approved products and a 52,000 sq ft purpose-built CDMO facility.
API ManufacturingFormulation DevelopmentProcess Development
Novartis Contract Manufacturing
Austria
Novartis Contract Manufacturing is the CDMO arm of Novartis, offering fully integrated end-to-end manufacturing solutions across biologics (mammalian up to 15,000L, microbial up to 13,000L), small molecules (API to fill & finish), cell & gene therapy (CAR-T, AAV, LV), xRNA/LNP/pDNA, and comprehensive fill & finish services. The operation spans multiple state-of-the-art facilities across Austria, Switzerland, Slovenia, Belgium, France, Singapore, and the United States, with 107 FDA inspections and 27 FEI registrations.
Frequently Asked Questions
What special capabilities do oncology CDMOs need?+
Oncology CDMOs need high-potency compound handling (OEB4/OEB5 containment with isolators and engineering controls), dedicated or segregated manufacturing suites to prevent cross-contamination, specialized waste handling for cytotoxic materials, worker safety programs including medical surveillance, and analytical methods validated for potent compound detection at very low levels. For ADCs, they additionally need bioconjugation suites and experience with linker-payload chemistry.
Why is containment critical for cancer drug manufacturing?+
Most oncology drugs are designed to kill rapidly dividing cells -- a property that makes them effective against tumors but hazardous to workers. Occupational exposure to cytotoxic compounds can cause skin irritation, reproductive harm, and potentially cancer. OEB4 and OEB5 containment (exposure limits below 1 microgram/m3) uses engineering controls -- isolators, airlocks, continuous liners, and HEPA-filtered exhaust -- to protect workers while maintaining product quality.
Need help finding the right CDMO?
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.
